WORLD PEPTIDEFOUNDATION

Where is Octreotide being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for Octreotide →Worldwide registry directory

Scientific intelligence record

Experience 2.0

Somatostatin analog

Octreotide

Octreotide is a synthetic cyclic octapeptide analog of somatostatin with greater metabolic stability and longer action than endogenous somatostatin. It binds predominantly somatostatin receptor subtypes 2 and 5, suppressing growth hormone and several gastroenteropancreatic hormones and secretions; effects therefore vary by receptor expression, disease, route, and formulation. Immediate-release injection, depot injection, and delayed-release oral products have distinct pharmacokinetics and regulatory labeling.

Record status

Traceability partial

Last meaningful update: 9/20/2026

Evidence searched through:
Not recorded
Assessment updated:
9/20/2026
Documented human review:
No documented human review recorded
Automated scientific assessment:
None recorded
AI source check:
9/26/2026

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

500

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

0

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

6

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

25

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observationArchive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

500

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

0

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

6

Independent evidence dossiers covering the major research questions.

Published source records

25

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

0

Conflicting evidence relationships that remain visible.

Research gaps

1

Questions the current record identifies as unresolved.

Connected media

0

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

6 published domain syntheses connected to 0 featured studies

Octreotide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas
Inspect the published evidence record25 governed records · titles, provenance, and original-source linksOpen records ↓
2021Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results.

Results are presented from 2 to 3 trials investigating oral octreotide capsules (OOC) as an alternative to injectable somatostatin receptor ligands (iSRLs) in the treatment of acromegaly.

Authors
Artak Labadzhyan, L B Nachtigall, M Fleseriu, M B Gordon, M Molitch, L Kennedy, S L Samson, Y Greenman, N Biermasz, M Bolanowski, A Haviv, W Ludlam
Source
Pituitary
DOI
10.1007/s11102-021-01163-2
PubMed
34173129
Open original source
2009Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs).

Authors
Anja Rinke, Hans-Helge Müller, Carmen Schade-Brittinger, Klaus-Jochen Klose, Peter Barth, Matthias Wied, Christina Mayer, Behnaz Aminossadati, Ulrich-Frank Pape, Michael Bläker, Jan Harder, Christian Arnold
Source
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DOI
10.1200/jco.2009.22.8510
PubMed
19704057
Open original source
2013Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly.

Acromegaly is caused by excessive GH secretion and IGF-I overproduction.

Authors
Carla Chieffo, David Cook, Qinfang Xiang, Lawrence A Frohman
Source
The Journal of clinical endocrinology and metabolism
DOI
10.1210/jc.2013-2262
PubMed
23969184
Open original source
2025Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly.

Octreotide is a first-generation somatostatin receptor ligand (SRL) approved for acromegaly treatment.

Authors
Anaïs Glatard, Sofia Friberg-Hietala, Lina Keutzer, Anna Hansson, Markus Johnsson, Fredrik Tiberg
Source
Clinical pharmacokinetics
DOI
10.1007/s40262-025-01522-3
PubMed
40418492
Open original source
2015Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.

Somatostatin analogues (SSA) have demonstrated antiproliferative activity in addition to efficacy for carcinoid symptom control in functional neuroendocrine tumors (NET).

Authors
Jonathan R Strosberg, James C Yao, Emilio Bajetta, Mounir Aout, Bert Bakker, John D Hainsworth, Philippe B Ruszniewski, Eric Van Cutsem, Kjell Öberg, Marianne E Pavel
Source
Endocrine-related cancer
DOI
10.1530/erc-15-0314
PubMed
26373569
Open original source
2024Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial: A FRENCH 007-ACHBT Study.

Pharmacological prevention of postoperative pancreatic fistula (POPF) after pancreatectomy is open to debate.

Authors
Sébastien Gaujoux, Jean-Marc Regimbeau, Guillaume Piessen, Stéphanie Truant, Frantz Foissac, Louise Barbier, Emmanuel Buc, Mustapha Adham, David Fuks, Sophie Deguelte, Fabrice Muscari, Laurent Sulpice
Source
Annals of surgery
DOI
10.1097/sla.0000000000006313
PubMed
38662619
Open original source
2015Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.

Hepatorenal syndrome (HRS), a serious complication of cirrhosis, is associated with high mortality without treatment.

Authors
Marta Cavallin, Patrick S Kamath, Manuela Merli, Silvano Fasolato, Pierluigi Toniutto, Francesco Salerno, Mauro Bernardi, Roberto Giulio Romanelli, Cosimo Colletta, Freddy Salinas, Antonio Di Giacomo, Lorenzo Ridola
Source
Hepatology (Baltimore, Md.)
DOI
10.1002/hep.27709
PubMed
25644760
Open original source
2010Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
70/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

There are no proven, effective therapies for polycystic kidney disease (PKD) or polycystic liver disease (PLD).

Authors
Marie C Hogan, Tetyana V Masyuk, Linda J Page, Vickie J Kubly, Eric J Bergstralh, Xujian Li, Bohyun Kim, Bernard F King, James Glockner, David R Holmes, Sandro Rossetti, Peter C Harris
Source
Journal of the American Society of Nephrology : JASN
DOI
10.1681/asn.2009121291
PubMed
20431041
Open original source
2010Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.

No medical treatment is available for polycystic liver disease, a frequent manifestation of autosomal-dominant polycystic kidney disease (ADPKD).

Authors
Anna Caroli, Luca Antiga, Mariateresa Cafaro, Giorgio Fasolini, Andrea Remuzzi, Giuseppe Remuzzi, Piero Ruggenenti
Source
Clinical journal of the American Society of Nephrology : CJASN
DOI
10.2215/cjn.05380709
PubMed
20185596
Open original source
2022Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Impact of Octreotide on Early Complications After Liver Transplant: A Randomized, Double-Blind Placebo-Controlled Trial.

Acute kidney injury and early allograft dysfunction are 2 common complications after liver transplant.

Authors
Kamran Bagheri Lankarani, Hoda Safa, Sulmaz Ghahramani, Mohammad Sayari, Seyed-Ali Malekhosseini
Source
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
DOI
10.6002/ect.2022.0080
PubMed
35867022
Open original source
2024Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Octreotide improves human lymphatic fluid transport a translational trial.

Chylothorax is a complex condition and many different pharmacological agents have been tried as treatment.

Authors
Thomas Holm-Weber, Frederik Skov, Sheyanth Mohanakumar, Lene Thorup, Troels Riis, Mikkel Bring Christensen, David Peick Sonne, Per Bo Jensen, Donna Briggs Bødtkjer, Vibeke Elisabeth Hjortdal
Source
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
DOI
10.1093/ejcts/ezad380
PubMed
37951584
Open original source
1995Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients.

Treatment of acromegaly with intermittent sc injections of octreotide is associated with an increased incidence of cholelithiasis.

Authors
J P Tauber, M F Poncet, A G Harris, H R Barthel, C Simonetta-Chateauneuf, L Buscail, F Bayard
Source
The Journal of clinical endocrinology and metabolism
DOI
10.1210/jcem.80.11.7593435
PubMed
7593435
Open original source
2006Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy.

Despite a strong rationale for trials of somatostatin analogs in the treatment of Graves' ophthalmopathy (GO), recent studies have provided conflicting results.

Authors
Marius N Stan, James A Garrity, Elizabeth A Bradley, John J Woog, Mark M Bahn, Michael D Brennan, Sandra C Bryant, Sara J Achenbach, Rebecca S Bahn
Source
The Journal of clinical endocrinology and metabolism
DOI
10.1210/jc.2006-1105
PubMed
16984988
Open original source
2015Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.

Does octreotide reduce vomiting in cancer-associated bowel obstruction?

Authors
David C Currow, Stephen Quinn, Meera Agar, Belinda Fazekas, Janet Hardy, Nikki McCaffrey, Simon Eckermann, Amy P Abernethy, Katherine Clark
Source
Journal of pain and symptom management
DOI
10.1016/j.jpainsymman.2014.09.013
PubMed
25462210
Open original source
1997Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis.

In this study, octreotide was not found to be of benefit in the treatment of acute pancreatitis.

Authors
C McKay, J Baxter, C Imrie
Source
International journal of pancreatology : official journal of the International Association of Pancreatology
DOI
10.1007/bf02785915
PubMed
9127169
Open original source
2008Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Randomized controlled trial comparing somatostatin with octreotide in the prevention of complications after pancreatectomy.

The postoperative morbidity following pancreaticoduodenectomy (PD) remains very high.

Authors
Jean Closset, Stephane Journe, Freddy Mboti, Issam El Nakadi, Michel Gelin
Source
Hepato-gastroenterology
PubMed
19102400
Open original source
2000Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Octreotide in acute bleeding esophageal varices: a prospective randomized study.

To assess the value of octreotide in the control of acute bleeding esophageal varices, in a prospective randomized study.

Authors
D S Freitas, C Sofia, J M Pontes, C Gregório, J P Cabral, P Andrade, A Rosa, E Camacho, M Ferreira, F Portela, J M Romãozinho, L Tomé
Source
Hepato-gastroenterology
PubMed
11100339
Open original source
2015Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.

The aim of this randomized controlled study was to determine whether octreotide (OCT) or scopolamine butylbromide (SB) was the more effective antisecretive drug controlling gastrointestinal (GI) symptoms due to malignant bowel obstruction (MBO) caused by advanced ovarian cancer.

Authors
Xingang Peng, Peige Wang, Shikuan Li, Guangyong Zhang, Sanyuan Hu
Source
World journal of surgical oncology
DOI
10.1186/s12957-015-0455-3
PubMed
25889313
Open original source
2011Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.

Treatment with somatostatin analogues is the primary medical treatment of acromegaly.

Authors
Sven M Carlsen, Johan Svartberg, Thomas Schreiner, Sylvi Aanderud, Oivind Johannesen, Svein Skeie, Morten Lund-Johansen, Stine L Fougner, Jens Bollerslev, POTA study group
Source
Clinical endocrinology
DOI
10.1111/j.1365-2265.2011.03982.x
PubMed
21521254
Open original source
2005Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.

The effect of octreotide plus interferon-alpha versus octreotide monotherapy on the primary study end points of time to treatment failure (progression, death, stop of study treatment) and long-term survival was investigated in patients with progressive metastatic neuroendocrine foregut (mainly pancreatic) and midgut tumors.

Authors
Rudolf Arnold, Anja Rinke, Klaus-Jochen Klose, Hans-Helge Müller, Matthias Wied, Karin Zamzow, Christina Schmidt, Carmen Schade-Brittinger, Peter Barth, Roland Moll, Michael Koller, Michael Unterhalt
Source
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
DOI
10.1016/s1542-3565(05)00481-7
PubMed
16234004
Open original source
2017Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.

Somatostatin analogs have been shown to control the growth of well-differentiated metastatic neuroendocrine tumors.

Authors
Anja Rinke, Michael Wittenberg, Carmen Schade-Brittinger, Behnaz Aminossadati, Erdmuthe Ronicke, Thomas M Gress, Hans-Helge Müller, Rudolf Arnold, PROMID Study Group
Source
Neuroendocrinology
DOI
10.1159/000443612
PubMed
26731483
Open original source
1999Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.

Subcutaneous (SC) octreotide acetate effectively relieves the diarrhea and flushing associated with carcinoid syndrome but requires long-term multiple injections daily.

Authors
J Rubin, J Ajani, W Schirmer, A P Venook, R Bukowski, R Pommier, L Saltz, P Dandona, L Anthony
Source
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DOI
10.1200/jco.1999.17.2.600
PubMed
10080605
Open original source
1992Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Octreotide treatment of acromegaly. A randomized, multicenter study.

To determine the effects of the somatostatin analog, octreotide acetate, in patients with acromegaly.

Authors
S Ezzat, P J Snyder, W F Young, L D Boyajy, C Newman, A Klibanski, M E Molitch, A E Boyd, L Sheeler, D M Cook
Source
Annals of internal medicine
DOI
10.7326/0003-4819-117-9-711
PubMed
1416572
Open original source
2024Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Standard of Care Versus Octreotide in Angiodysplasia-Related Bleeding (the OCEAN Study): A Multicenter Randomized Controlled Trial.

Gastrointestinal angiodysplasias are vascular anomalies that may result in transfusion-dependent anemia despite endoscopic therapy.

Authors
Lia C M J Goltstein, Karina V Grooteman, Lucas H P Bernts, Robert C H Scheffer, Robert J F Laheij, Lennard P L Gilissen, Ruud W M Schrauwen, Nynke C Talstra, Abraham T Zuur, Henri Braat, Muhammed Hadithi, Johannes T Brouwer
Source
Gastroenterology
DOI
10.1053/j.gastro.2023.12.020
PubMed
38158089
Open original source
2018Observational human evidence
Evidence strength A · 88/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Octreotide for congenital and acquired chylothorax in newborns: A systematic review.

Chylothorax is a rare but life-threatening condition in newborns.

Authors
Carlo Bellini, Rita Cabano, Laura C De Angelis, Tommaso Bellini, Maria G Calevo, Paolo Gandullia, Luca A Ramenghi
Source
Journal of paediatrics and child health
DOI
10.1111/jpc.13889
PubMed
29602276
Open original source

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓
Chemical identity

Molecular and structural record

Structured record
Molecular formula
C49H66N10O10S2
Molecular weight (Da)
1019.2
Amino acid sequence
[D-Phe]-Cys-Phe-[D-Trp]-Lys-Thr-Cys-Thr-ol; Cys2-Cys7 disulfide
SMILES
C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O
InChI
InChI=1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1
InChIKey
DEQANNDTNATYII-OULOTJBUSA-N

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Research discovery

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

  1. 1992 · study · Temporal status not established

    Octreotide treatment of acromegaly. A randomized, multicenter study.

    Annals of internal medicine

  2. 1995 · study · Temporal status not established

    The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients.

    The Journal of clinical endocrinology and metabolism

  3. 1997 · study · Temporal status not established

    A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis.

    International journal of pancreatology : official journal of the International Association of Pancreatology

  4. 1999 · study · Temporal status not established

    Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

  5. 2000 · study · Temporal status not established

    Octreotide in acute bleeding esophageal varices: a prospective randomized study.

    Hepato-gastroenterology

  6. 2005 · study · Temporal status not established

    Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

  7. 2006 · study · Temporal status not established

    Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy.

    The Journal of clinical endocrinology and metabolism

  8. 2008 · study · Temporal status not established

    Randomized controlled trial comparing somatostatin with octreotide in the prevention of complications after pancreatectomy.

    Hepato-gastroenterology

  9. 2009 · study · Temporal status not established

    Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

  10. 2010 · study · Temporal status not established

    Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

    Journal of the American Society of Nephrology : JASN

  11. 2010 · study · Temporal status not established

    Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide.

    Clinical journal of the American Society of Nephrology : CJASN

  12. 2011 · study · Temporal status not established

    Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.

    Clinical endocrinology

  13. 2013 · study · Temporal status not established

    Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly.

    The Journal of clinical endocrinology and metabolism

  14. 2015 · study · Temporal status not established

    Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.

    Endocrine-related cancer

  15. 2015 · study · Temporal status not established

    Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.

    Hepatology (Baltimore, Md.)

  16. 2015 · study · Temporal status not established

    Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.

    Journal of pain and symptom management

  17. 2015 · study · Temporal status not established

    Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.

    World journal of surgical oncology

  18. 2017 · study · Temporal status not established

    Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.

    Neuroendocrinology

  19. 2018 · study · Temporal status not established

    Octreotide for congenital and acquired chylothorax in newborns: A systematic review.

    Journal of paediatrics and child health

  20. 2021 · study · Temporal status not established

    Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results.

    Pituitary

  21. 2022 · study · Temporal status not established

    Impact of Octreotide on Early Complications After Liver Transplant: A Randomized, Double-Blind Placebo-Controlled Trial.

    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation

  22. 2024 · study · Temporal status not established

    Somatostatin Versus Octreotide for Prevention of Postoperative Pancreatic Fistula: The PREFIPS Randomized Clinical Trial: A FRENCH 007-ACHBT Study.

    Annals of surgery

  23. 2024 · study · Temporal status not established

    Octreotide improves human lymphatic fluid transport a translational trial.

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery

  24. 2024 · study · Temporal status not established

    Standard of Care Versus Octreotide in Angiodysplasia-Related Bleeding (the OCEAN Study): A Multicenter Randomized Controlled Trial.

    Gastroenterology

  25. 2025 · study · Temporal status not established

    Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly.

    Clinical pharmacokinetics

  26. 2026 · regulatory · Temporal status not established

    Regulatory review: approved

    United States (FDA — MYCAPSSA)

  27. 2026 · regulatory · Temporal status not established

    Regulatory review: approved

    United States (FDA — SANDOSTATIN LAR DEPOT)

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Researchers represented in the evidence record12 bibliographic identities · open to inspect

These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.

Anja Rinke

3 represented evidence records

Years represented: 2005, 2009, 2017

Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Neuroendocrinology

Carmen Schade-Brittinger

3 represented evidence records

Years represented: 2005, 2009, 2017

Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Neuroendocrinology

Hans-Helge Müller

3 represented evidence records

Years represented: 2005, 2009, 2017

Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Neuroendocrinology

Behnaz Aminossadati

2 represented evidence records

Years represented: 2009, 2017

Publishing organizations appearing in records: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Neuroendocrinology

Klaus-Jochen Klose

2 represented evidence records

Years represented: 2005, 2009

Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Matthias Wied

2 represented evidence records

Years represented: 2005, 2009

Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Peter Barth

2 represented evidence records

Years represented: 2005, 2009

Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Rudolf Arnold

2 represented evidence records

Years represented: 2005, 2017

Publishing organizations appearing in records: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, Neuroendocrinology

A E Boyd

1 represented evidence record

Years represented: 1992

Publishing organizations appearing in records: Annals of internal medicine

A G Harris

1 represented evidence record

Years represented: 1995

Publishing organizations appearing in records: The Journal of clinical endocrinology and metabolism

A Haviv

1 represented evidence record

Years represented: 2021

Publishing organizations appearing in records: Pituitary

A Klibanski

1 represented evidence record

Years represented: 1992

Publishing organizations appearing in records: Annals of internal medicine

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Open 12 represented connections ↓

institution

The Journal of clinical endocrinology and metabolism

represented evidence source

institution

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

represented evidence source

institution

Hepato-gastroenterology

represented evidence source

institution

Pituitary

represented evidence source

institution

Clinical pharmacokinetics

represented evidence source

institution

Endocrine-related cancer

represented evidence source

institution

Annals of surgery

represented evidence source

institution

Hepatology (Baltimore, Md.)

represented evidence source

institution

Journal of the American Society of Nephrology : JASN

represented evidence source

institution

Clinical journal of the American Society of Nephrology : CJASN

represented evidence source

institution

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation

represented evidence source

institution

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery

represented evidence source

Traceability

Follow the record back to its source

The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.

Source publication state

A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Domain conclusion → Evidence

Connected

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Reconciled for 6 domain conclusions and 0 featured studies.

Detailed study-to-domain mappings and original-source paths appear in the Octreotide evidence-governance section.

Inspect the ranked source records

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Published jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.
Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.
Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.
Contradictory and qualifying evidence must remain visible rather than being silently discarded.
Absence of represented evidence is not evidence that research does not exist.
Research gaps identify unresolved questions; they are not negative conclusions.
Regulatory status is distinct from scientific evidence quality.
Media relationships provide context and explanation; they do not increase the strength of scientific evidence.
A section with no represented records is an incomplete project record, not a scientific conclusion.
Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.

Generated: 11/8/2026, 5:25:04 PM

global evidence atlas

Octreotide research, ranked and separated by purpose

This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

713Discoverable source universe
500Ranked screening records
6Research domains
0Accountably approved conclusions

500 matching records · ranked 2026-09-18

Page 1 of 20

Count reconciliation: 713 discoverable source records match the peptide identity query; 500 are retained in this bounded, ranked screening view; 0 belong to the separate governed layer labeled “Accountably approved conclusions.” Domain totals overlap because one publication may inform several questions.

governance and regulatory context

Octreotide: what this atlas does and does not establish

Last checked
2026-09-18
Accountable publication approval
Not yet approved by a named accountable reviewer. Machine screening only.

No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.

Regulatory status by jurisdiction

Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.

  • United States (FDA — MYCAPSSA)approvedchecked 2026-09-09

    MYCAPSSA octreotide delayed-release capsules are FDA-approved for long-term maintenance treatment in acromegaly patients who responded to and tolerated octreotide or lanreotide, according to current labeling.

    FDA Drugs@FDA — MYCAPSSA NDA 208232
  • United States (FDA — SANDOSTATIN LAR DEPOT)approvedchecked 2026-09-09

    SANDOSTATIN LAR DEPOT is FDA-approved for long-term maintenance treatment in acromegaly after response and tolerance to subcutaneous octreotide, and for long-term treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and profuse watery diarrhea associated with VIP-secreting tumors, under current label criteria.

    FDA Drugs@FDA — SANDOSTATIN LAR DEPOT NDA 021008

5 FDA structured product label record(s) were identified for this compound name in openFDA. Label presence reflects an approved product exists under that name; it is not a claim about the specific formulation, dose, or use being discussed anywhere else on this page.

No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review.

Octreotide evidence · ranking key

How evidence is ranked

A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.

A

Practice-defining evidence

Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.

B

Strong supporting evidence

Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.

C

Contextual evidence

Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.

D

Signal-generating evidence

Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.

Tier and confidence answer different questions

Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.

Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.

Suggested citation

  • APA

    World Peptide Foundation. (n.d.). Octreotide — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 20, 2026.) https://www.worldpeptidefoundation.org/directory/octreotide

  • AMA / Vancouver

    World Peptide Foundation. Octreotide — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 20, 2026. https://www.worldpeptidefoundation.org/directory/octreotide